Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
- 21 December 2022
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 200 (6) , 731-739
Abstract
Summary: In the H10 and RAPID randomised trials, chemotherapy+radiotherapy (combined modalities treatment, CMT) was compared with chemotherapy (C) in limited‐stage Hodgkin lymphoma (HL), with negative early positron emission tomography (ePETneg). We analysed patterns of relapses in the H10 trial, validated findings in the RAPID trial and performed a combined analysis stratified by trial. The impact of radiotherapy (RT) on risk of relapse was studied using adjusted Cox models, with time‐varying effects. In H10, 1,059 ePETneg patients were included (465 European Organisation for Research and Treatment of Cancer (EORTC) favourable [F], 594 unfavourable [U]). Among the F patients, 2/227 (1%) relapsed after CMT, 30/238 (13%) after C: of these relapses, 21/30 (70%) occurred in less than 2 years and 25/30 (83%) affected originally involved areas. Among the U group, 16/292 (5%) relapsed after CMT: 8/16 (50%) in less than 2 years, 11/16 (69%) in originally involved areas. After C 30/302 (10%) relapsed: 27/30 (90%) in less than 2 years, and 26/30 (87%) in originally involved areas. Similar results were observed in 419 ePETneg RAPID patients (241 F, 128 U, 50 unclassified): among F patients, 6/118 (5%) relapsed after CMT; 13/123 (11%) after C: 11/13 (85%) in less than 2 years and 11/13 (85%) affecting originally involved areas. In U patients, 3/65 (5%) relapsed after CMT and 5/63 (8%) after C. In both trials, omitting RT in ePETneg HL resulted in more early relapses, mainly affecting originally involved areas. RT significantly reduced risk of early relapses in the combined stratified analysis.Keywords
Funding Information
- Cancer Research UK
- Department of Health and Social Care
- Medical Research Council
- National Institute for Health Research (RP‐2‐16‐07‐001)
- National Institute for Health Research
- National Institute for Health Research
- Engineering and Physical Sciences Research Council (WT203148/Z/16/Z)
This publication has 15 references indexed in Scilit:
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Cardiovascular Disease After Hodgkin Lymphoma TreatmentJAMA Internal Medicine, 2015
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)American Journal of Hematology, 2015
- The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleHaematologica, 2014
- Treatment of Hodgkin Lymphoma: A 50-Year PerspectiveJournal of Clinical Oncology, 2014
- Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patientTherapeutic Advances in Hematology, 2011
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Checking the Cox Model with Cumulative Sums of Martingale-Based ResidualsBiometrika, 1993